Bone Metabolism Biomarkers, Bone Mineral Density, Physical Fitness
Conditions
Brief summary
This research will examine the effectiveness of vitamin D or placebo (the placebo is a tablet that looks like Vitamin D study drug, but has no Vitamin D study drug in it), with and without physical activity (walking and progressive resistance exercise), in treating bone loss in women who have undergone treatment for breast cancer. The investigators would also like to find out if the physical activity program improves cardiovascular fitness, energy expenditure, muscular strength, muscle mass, and balance. One hundred five (105) subjects are expected to take part in this study. The investigators don't know if bone loss in breast cancer survivors should be treated differently than bone loss in other women.
Interventions
DRUGVitamin D3
Vitamin D3 50,000 IU
BEHAVIORALPhysical Activity
Progressive walking and resistance band exercise prescription for a period of 24 weeks
Sponsors
University of Rochester
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Must be female and have a primary diagnosis of Stage I, II, or III hormone-receptor positive breast cancer. * Women must be postmenopausal at time of enrollment. * Must provide informed consent. * Must be willing to discontinue use of calcium and/or vitamin D supplements. * Participants must have an ionized serum calcium level within normal limits (1.19-1.29mmol/L) and a total corrected serum calcium of \< 10.6 mg/dl. * Participants must be slightly vitamin D deficient (serum vitamin D level \<32ng/ml) * Must have a functional capacity rating of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) performance status when assessed at baseline.132 * Must have the approval of their treating physician (or physician's nurse practitioner or physician's assistant) to participate in sub-maximal physiological fitness testing and a low to moderate home-based walking and progressive resistance exercise program and to receive the 24-week supplementation of vitamin D. * Must be less than five years from the diagnosis of breast cancer and must be within 12 months of starting treatment with aromatase inhibitors (AI) in accordance with American Society of Clinical Oncology (ASCO) guidelines.
Exclusion criteria
* Subjects with life-threatening conditions that would preclude them from breast cancer treatment including chronic cardiac failure, which is unstable despite medication use, uncontrolled hypertension, uncontrolled diabetes mellitus, or unstable coronary artery disease. * Patients who had a myocardial infarction within the past year. * Patients with severe metabolic disorders, which includes phenylketonuria (PKU), homocystinuria, and Fabry's disease, that would preclude them from taking calcitriol. * Patients with impaired renal function (CRCL \< 60 mL/min) or who had kidney stones (calcium salt) within the past 5 years. * Patients with hypercalcemia (corrected serum Ca ≥ 10.6 mg/dl) or a history of hypercalcemia or vitamin D toxicity. * Patients currently taking calcium supplements or aluminum-based antacids must be willing to discontinue their use if they are to enroll in the study. * Patients currently taking vitamin D supplements must immediately discontinue their use if they are to enroll in the study. * Patients with a known sensitivity to vitamin D. * Patients who are severely vitamin D deficient (\<10 ng/ml). * Women on antiresorptive drugs (e.g. bisphosphonates) within the past year. * Patients not capable of participating in an exercise intervention due to severe knee arthrosis or ligament/cartilage injuries of the lower extremities. * Women with malabsorptive syndromes (i.e. cystic fibrosis, chronic pancreatitis) or taking medications that decrease the absorption of fat soluble vitamins (i.e. Orlistat, Questran).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure the Amount of Bone Mineral Density Loss in Non-metastatic Breast Cancer Patients Receiving a High Dose Vitamin D Therapy Along With a Structured Home-based Walking and Progressive Resistance Exercise Program. | 24 weeks | To collect preliminary data on the effects of vitamin D therapy and exercise (alone or in combination) on bone mineral density (BMD) as measured by a dual energy X-ray absorptiometry (DXA) in non-metastatic breast cancer patients who began hormonal therapy within the previous 12 months. Amount of bone loss was measured with change in BMD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measure the Effect of Vitamin D and Muscle Strength in Non-metastatic Breast Cancer Patients | 24 weeks | Measuring physical fitness for muscle strength using handgrip dynamometer in non-metastatic breast cancer patients who begin hormonal therapy within the previous 12 months. |
| Measure the Effect of Vitamin D and Aerobic Capacity in Non-metastatic Breast Cancer Patients | 24 Weeks | Pedometer for number of steps for aerobic capacity. |
| Measure the Effect of Vitamin D and Balance in Non-metastatic Breast Cancer Patients | 24 weeks | Testing Force Plate Area95 Eyes Closed Open Base for measure of balance |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORLuke J Peppone, PhD, MPH
University of Rochester
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 63.1 Years STANDARD_DEVIATION 7.6 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants |
| Race (NIH/OMB) White | 31 Participants |
| Sex: Female, Male Female | 35 Participants |
| Sex: Female, Male Male | 0 Participants |
| Stage 0 | 12 Participants |
| Stage 1 | 60 Participants |
| Stage 2 | 28 Participants |
| Stage 3 | 3 Participants |
| Stage Unknown | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 34 | 0 / 36 | 0 / 35 |
| other Total, other adverse events | 3 / 34 | 6 / 36 | 3 / 35 |
| serious Total, serious adverse events | 0 / 34 | 0 / 36 | 0 / 35 |
Outcome results
None listed